The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Victrelis™ (boceprevir) and Hepatitis C

What if one has an adverse reaction to the Victrelis™ combination therapy?

UPDATE: As of January 2015 Merck announced it will discontinue selling Victrelis in the United States by the end of the year.

Reducing the dosage of Victrelis™ is not recommended by Merck. However, if one experiences an adverse reaction that is possibly related to the peginterferon alfa and/or ribavirin, the peginterferon alfa and/or ribavirin dosage could be reduced or discontinued based on the information provided in these medications’ Package Inserts regarding how to reduce and/or discontinue peginterferon alfa and/or ribavirin dose.

Victrelis™ cannot be administered if peginterferon alfa and ribavirin are discontinued.

Last Updated: January 2015

Merck "Highlights of Prescribing Information - Victrelis" http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Retrieved May 18, 2011.

Merck "Medication Guide - Victrelis™" http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_mg.pdf. Retrieved May 18, 2011.

Merck "Patient Assistance Programs" http://www.merck.com/responsibility/pap-information.html. Retrieved May 23, 2011.

Neutropenia Support Association, Inc. "What is Neutropenia?" http://www.neutropenia.ca/. Retrieved May 19, 2011.

Victrelis http://victrelis.com/boceprevir/victrelis/consumer/index.jsp. Retrieved May 23, 2011.